Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Schrodinger Inc. Stock

Price
Target price
€21.62

€21.62

-1.810%
-0.4
-1.810%
€100.00
 
08.05.24 / Tradegate WKN: A2PY7M / Name: Schrodinger Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Schrodinger Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Schrodinger Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Schrodinger Inc.

sharewise wants to provide you with the best news and tools for Schrodinger Inc., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2024, the company

BusinessWire_EN 
0 18.04.24
Schrödinger to Announce First Quarter 2024 Financial Results on May 1: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger to Announce First Quarter 2024 Financial Results on May 1


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2024 financial results on

BusinessWire_EN 
0 10.04.24
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1

BusinessWire_EN 
0 20.03.24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on March 15, 2024, the company

BusinessWire_EN 
0 19.03.24
Schrödinger to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger to Participate in Upcoming Investor Conferences


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the

BusinessWire_EN 
0 20.02.24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on February 13, 2024, the company

BusinessWire_EN 
0 16.02.24
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2023 financial

BusinessWire_EN 
0 14.02.24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2024, the company

BusinessWire_EN 
0 19.01.24
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company

BusinessWire_EN 
0 19.12.23
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, is providing a detailed review of its proprietary drug

BusinessWire_EN 
0 14.12.23
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting: https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting


Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced new preclinical data on SGR-1505, its

BusinessWire_EN 
0 10.12.23
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20230427005076/en/1376196/5/New_Logo.jpg
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 13, 2023, the company

BusinessWire_EN 
0 17.11.23